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In eukaryotes P-type ATPases are represented by a superfamily of membrane ion and 
lipid transporters divided into five subclasses. Substrates for classes 1-4 have been identified, 
however little is known about the substrate specificity of the P-type 5A and 5B transporters. 
Here we show that the Drosophila gene anne boleyn encodes a family of six P5B-type 
ATPases. Using a combination of RNAi, insertional mutagenesis, and CRISPR-Cas9 gene 
editing we show that some of these isoforms are required for polyamine transport and others 
are not. In addition, we show that the Drosophila P5A-type ATPase, encoded by CG6230 is not 
required for polyamine transport, indicating a different substrate specificity for this transporter 
sub-family. In summary, we provide evidence for the first time for an evolutionary conserved 
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Polyamines are small cationic molecules ubiquitous to all eukaryotes. The major 
polyamines, putrescine, spermidine and spermine, are essential for basic cellular processes 
including cell proliferation and growth, gene regulation, cell cycle control, apoptosis, and 
translational control (1, 2, 3, 4, 5). Polyamine homeostasis is maintained by a combination of 
biosynthesis, transport, and degradation. Ornithine decarboxylase (ODC) catalyzes the first, 
rate-limiting step of polyamine biosynthesis, decarboxylating ornithine and producing putrescine. 
(Figure 1) Putrescine acts as a substrate for SPD synthase, synthesizing spermidine by the 
addition of an aminopropyl group. Another aminopropyl group is used by SPM synthase to 
convert spermidine to spermine. Aminopropyl groups required for polyamine synthesis are 
donated from the methionine cycle. S-adenosylmethionine (SAM) is decarboxylated by S-
adenosylmethionine decarboxylase (SamDC). The resulting aminopropyl group, decarboxylated 
SAM (dcSAM), acts as the aminopropyl donor for the converting putrescine to spermidine and 
spermine (1, 6).  
Cellular polyamines content is also regulated by back conversion involving oxidation or 
acetylation. Spermine can be degraded by spermine oxidase (SMOX) to produce spermidine 
directly. Alternatively, spermine and spermidine can be acetylated by spermine/spermidine N-
acetyltransferase (SAT1). N-acetylated spermine/spermidine is either exported from the cell or 
further oxidized by polyamine oxidase (PAOX) to produce spermidine/putrescine.  (1, 2, 3, 5). 
Biosynthesis is highly regulated based on cellular polyamine concentrations (Figure 1). 
When the intracellular concentration of polyamines is high, antizyme acts to repress 









A. Putrescine is synthesized from ornithine by ornithine decarboxylase (ODC). Putrescine is 
used as a substrate for SPD synthase (SRM) to synthesize spermidine.  Spermidine is 
subsequently used as a substrate for spermine synthase (SMS) to form spermine.  DFMO 
inhibits the first step of polyamine biosynthesis by irreversible inhibition of ODC.  
B. Current models for mammalian polyamine transport. 
Figure 1. Polyamine biosynthesis pathway (14, 53) 
 
In addition to biosynthesis and export, cells also maintain polyamine homeostasis 
through transport from the extracellular environment (1, 2, 5). Interestingly, when intracellular 
polyamine levels are high, antizyme inhibits polyamine transport at the plasma membrane (58, 
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59) and stimulates the excretion of polyamines (60). It remains unresolved precisely how this 
occurs mechanistically. The polyamine transport system is poorly understood in higher 
eukaryotes, however components of polyamine transport in single-celled prokaryotes and 
eukaryotes have been identified. Uptake and efflux in Escherichia coli is controlled by the ATP-
binding cassette (ABC) and amino acid-polyamine-organocation (APC) transporter super-
families. The ABC family of transporters are encoded by the PotABCD and PotFGHI operons, 
which transport spermidine or putrescine, respectively (9). 
Saccharomyces cerevisiae have multiple genes responsible for polyamine transport. 
GAP1 is a general amino acid transporter located on the plasma membrane with affinity for 
putrescine and spermidine, but not spermine (21). Also involved in transport are the TPO1-4 
family of plasma membrane proteins which have structural similarities to the E. coli transport 
system (9). None of the bacterial or yeast genes identified have orthologs in higher eukaryotes 
(13).  
Multiple components of polyamine transport in higher eukaryotes have been identified, 
however, a cohesive framework of understanding remains elusive. One study found that 
spermine was imported through herapan sulfate side chains on glypican-1, sequestered within 
an endosome, and then released from herapan sulfate by nitric oxide synthetase 2 (20). Another 
study found that knock down of caveolin-1, which inhibits caveolar endocytosis, caused 
increased intracellular polyamine pools in colorectal cancer cells (21). In addition, genes within 
the solute carrier superfamily (SLC) have also been reported to have a role in transport. For 
instance, SLC32A2 has been identified as a plasma membrane bound putrescine exporter in 
colon epithelial cells (16). Other examples include SLC3A2 (16), SLC18B1 (17), SLC22A1 (28), 
SLC12A8A (29) and SLC22A16 (30). 
Based on all these observations, a general model was proposed by Poulin in which 
uptake occurs via an unidentified polyamine transporter at the plasma membrane, and cytosolic 
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polyamines are sequestered into vesicles (see Figure 1B). In this model, the cell acquires 
polyamines through transport at the plasma membrane through caveolar, glypican or receptor 
mediated endocytosis. Polyamines are exchanged between a cytoplasmic pool and gradually 
maturing endocytic vesicles, regulating cellular polyamine concentrations. 
The sequestration of cytoplasmic polyamines into vesicles is a compelling explanation 
as uptake of polyamines would occur under thermodynamically favorable conditions. Thus, by 
regulation of cytoplasmic polyamine pools, through vesicle sequestration, cells would passively 
regulate uptake at the plasma membrane (10, 11). This two-step model for transport has been 
supported by subsequent research (12, 15). Despite numerous studies, our current 
understanding of polyamine transport in multicellular eukaryotes is confounded by the lack of in 
vivo studies and the tissue complexity of higher eukaryotes.  
The Role of P-type ATPases in Polyamine Transport 
The polyamine transport mechanisms (uptake and efflux) are poorly understood, despite 
both biosynthesis and degradation being well characterized, which highlights a fundamental gap 
in our biological knowledge. A recent study in C. elegans attempts to rectify this gap by 
identifying a gene, CATP-5, which encodes a plasma membrane transporter necessary for 
polyamine uptake in vivo (7).  
CATP-5 belongs to a highly conserved superfamily of transport proteins, P-type 
ATPases, which are ATP-dependent and responsible for cationic and phospholipid transport. 
(8,9). The P-type ATPase superfamily can be divided into five families (P1-P5) and sub-families 
based on ligand specificity. P1-P4 type transporters have well characterized ligand specificities, 
however the ligand(s) for P-type 5 ATPases remains unknown (8). P-type ATPases have been 
identified in almost all organisms suggesting they are vital for all domains of life (31). 
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Functionally, P-type ATPases are best understood through their domain structure 
(Figure 2). They have two structurally important domains composing the core transmembrane 
segment: a transport (T) domain and a support (S) domain (8). The structure of the support 
domain is variable between the different classes of P-type ATPases. Interestingly, some P-type 
ATPases are more homologous to their specific class across species than to different classes 
within the same organism (31). Most, but not all P-type ATPases have a third regulatory domain 
(R) at either the C or N-terminus (8). The support and regulatory (if present) domains serve 




All classes of P-type ATPases contain a transport (T) domain composed of six transmembrane 
alpha-helices and a support (S) domain with a variable number of transmembrane domains. The 
transport domain contains three cytoplasmic sub-domains: actuator domain (A), phosphorylation 
domain (P), and nucleotide binding domain (N).    
Figure 2: Structure of P-type ATPases (8) 
 
The transport domain is composed of six highly conserved transmembrane core 
segments and contains regions responsible for catalytic activity and substrate recognition. 
Within the conserved transmembrane segment of the transport domain are three sub-domains: 
the nucleotide binding domain (N) which initially binds ATP, the phosphorylation domain (P) 
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which contains a highly conserved, invariant aspartic acid residue responsible for catalytic 
activity, and an actuator domain (A) which acts as a phosphatase to regulate activity of the 
phosphorylation domain. 
The catalytic mechanism of action is as follows: the nucleotide binding domain binds 
ATP and phosphorylates the aspartic acid residue of the phosphorylation domain. A shift in the 
conformation of the protein occurs, exposing a region that has high affinity for a ligand in the 
extracellular space. The ligand binds on the extracellular face causing the conformation to 
change again, releasing the ligand into the cytosol (8). 
Drosophila as a Model for Studying Polyamine Transport 
While a few genes involved with mammalian polyamine transport have been studied, it is 
unclear exactly how each component works together to transport polyamines, representing a 
fundamental gap in our knowledge. Our goal was to build on the work done on the C. elegans 
polyamine transporter (CATP-5) by using Drosophila as a model system to study polyamine 
transport in vivo. The Drosophila genome contains two orthologs to CATP-5.  Both orthologs, 
CG6230 and anne boleyn (anne), encode P-type 5 ATPases that vary by sub-family.  CG6230 
encodes a 5A sub-family ATPase while anne encodes a 5B P type ATPase.   
anne is a 10.9 kilobase complex locus encoding six different P-type ATPase protein 
isoforms, all of which contain a transport domain composed of five core exons (Figure 3). A 
conserved aspartic acid residue, required for ATPase activity in all P-type ATPases, is located 
on the end of the transport domain (Figure 3C).  This gene also encodes support domains 
varying by isoform due to alternatively spliced 5' and 3' exons (Figure 3A).  Five of the isoforms 
encode for an integral membrane protein with 11 transmembrane domains (Figure 3B).  The 6th 
isoform composed of either alternatively 5' exon, the core exons, and the X exon encodes a 










A.  Gene layout of anne. The translation start codon is indicated by *.  The translation stop 
codon indicated by **.   
B.  Potential protein isoforms of anne. The A and B exons have not been observed together in 
full length cDNAs. – You should correct the Figure because it gives the impression that the A 
and B exons are found together in full length cDNAs which is not true. Only A and A’A have 
been seen in full length cDNAs.  
C.  Domain structure of anne.  The domain structure is organized into 11 transmembrane 
domains and three cytoplasmic domains responsible for ATPase activity. The phosphorylation 
domain (P) is composed of a highly conserved aspartic acid residue (Yellow star) responsible 
for catalytic activity.  The A, A’, and B exons are located extracellular.  The X isoform is 
truncated compared to other isoforms. 
Figure 3: Structural organization of the CG32000 locus exons and domain structure. 
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Goals of this Thesis 
The main goal of this thesis was to leverage the powerful genetic tools available for 
Drosophila to test whether the Drosophila CATP-5 orthologs encode polyamine transporters.  
An improved understanding of the polyamine transport system in a higher eukaryote has 
both basic biological and clinical significance. All metazoans transport polyamines, yet our 
understanding of the transport mechanism is limited to unicellular organisms. Tumor cells 
require high polyamine concentrations to sustain rapid growth and proliferation (1,2,3,5).  A 
clinically approved drug, α-difluoromethylornithine (DFMO), is highly effective at inhibiting 
biosynthesis by acting as an irreversible inhibitor of ODC. (Figure 1) However many tumors 
circumvent the effects of DFMO by up-regulating polyamine uptake. (3,5) Thus, a combined 
therapy that targets biosynthesis and transport may be more effective in treating cancers. 
Understanding how the P-type 5 ATPase sub-family interacts with polyamines, a hypothesized 




CRISPR Guide RNA (gRNA) Design 
The FlyCRISPR algorithm was used to design gRNAs and identify potential off-target 
cleavage sites. For creating defined deletions, two gRNAs surrounding the targeted genomic 
region were constructed.  Only one gRNA was generated to create mutant flies with a single 
nucleotide substitution.  The algorithm returns an output of two 20nt long oligonucleotides, for 
both the sense and antisense strands, homologous to the targeted region.  Additional 
overhangs were added to both the sense (5’-CTTC-3') and antisense (3’-CAAA-5') 
oligonucleotides for restriction enzyme cloning as well as an extra ‘G’ in the sense 
oligonucleotide to facilitate expression efficiency when placed in the pU6-BbsI-chiRNA vector. 
Construction of pU6-gRNA (chiRNA) Plasmids 
All oligonucleotides were ordered from Sigma-Aldrich.  The 5’ end of each 
oligonucleotide was phosphorylated using T4 polynucleotide kinase and annealed following the 
manufacturer's specifications.  pU6-BbsI-chiRNA vector was ordered from Drosophila Genomic 
Resource Center, stock #1363 (61), purified with a Qiagen mini-prep kit, restriction enzyme 
digested with BbsI, and gel purified using a Promega Wizard SV gel and PCR clean-up kit. 
Annealed gRNA oligos were ligated into the pU6-BbsI-chiRNA vector using T4 DNA Ligase and 
transformed into DH5 component E.coli cells.  The gRNA plasmids were purified using a 
Qiagen mini-prep kit and subsequently underwent Sanger sequencing to identify vectors 
containing the correctly oriented gRNA sequence.  Positive colonies were grown overnight and 
the gRNAs containing pU6-BbsI-chiRNA plasmids were purified using a Qiagen midi-prep kit. 
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Embryo Injection of pU6-gRNA (chiRNA) Plasmids 
Act5C-Cas9 (BL 54590) embryos were injected with 250ng/uL of plasmids containing 
gRNA sequences.  For defined deletions, 250ng/uL of each pU6-gRNA was injected (one 
targeting upstream of gene, one targeting downstream of gene).  For the single nucleotide 
substitution, a single pU6-gRNA plasmid was injected at a concentration of 250ng/uL along with 
100ng/uL of the single-stranded donor template (ssODN). 
Crossing Scheme for Creating Isogenic Mutant Lines  
Injected Act5C-Cas9 adults were collected and individually crossed to a BL464 4th 
chromosome balancer (eY/CiD) stock. Progeny from each founder cross were collected and 
approximately five males and five female siblings were mated. F1 flies were cleared, frozen with 
liquid nitrogen, and their DNA was extracted using a Qiagen DNeasy Blood and Tissue kit. 
Purified DNA from each F1 cross was amplified using Platinum Taq polymerase following the 
manufacturer's guidelines and primer specific annealing temperatures.  PCR products were 
visualized using agarose gel electrophoresis and fly lines containing mutant alleles were 
identified.  Single mating crosses were set-up between F2 and the eY/CiD (BL464) balancer 
animals to create an isogenic background for each potential mutant allele.  F3 virgin progeny 
that were phenotypically CiD were collected and crossed as single mating’s between siblings to 
set-up stable lines.  Progeny from F3 crosses that were not phenotypically CiD were collected, 
and DNA was extracted individually from these flies using Microlysis-PLUS DNA extraction 
buffer. 
The DNA extracted from individual flies was then amplified as described above and 
visualized by agarose gel electrophoresis.  Lines which produced the expected mutant PCR 
product were subsequently analyzed by Sanger sequencing. 
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Crossing Scheme for driving RNAi expression 
 
Animals containing the ubiquitously expressed promoter (Actin5C>GAL4; BL 25374) 
were crossed to animals carrying a UAS>RNAi construct targeting anne or CG6230. In the 
progeny of this cross GAL4 binds to UAS resulting in expression of RNAi and knockdown of 
candidate genes. 
Polyamine Transport Assay 
Approximately 200 female virgins (Actin5C>GAL4) and 50 males (UAS>RNAi) were 
crossed in a cage attached to plates containing grape juice agar and yeast paste.  Cages were 
incubated at 25C for at least 2 days with the grape agar plate changed daily. To obtain 
synchronous newly hatched larvae, the grape plate was exchanged hourly (twice) to encourage 
females to lay any fertilized eggs they might be holding. Females were then allowed to lay for 
four hours on a fresh plate and the plate was incubated at 25C until larvae began to hatch, 
typically 22 hours. 50 freshly hatched larvae were picked per treatment vial. 
Treatment vials contained instant food (Jazz Mix, Fisher Scientific) and a variable 
mixture of DFMO/polyamines based on treatment condition.  Jazz Mix food for treatment vials 
was prepared following manufacturer's instructions.  DFMO and polyamines for each individual 
treatment were dissolved in water and mixed into freshly made food after cooling to 50C.  Eight 
treatment conditions were tested; 1) Water only, 2) 5mM-35mM DFMO only, 3) 0.4mM 
Putrescine only, 4) 5mM (or 35mM) DFMO + 0.4mM Putrescine, 5) 0.2mM Spermidine only, 
6) 5mM (or 35mM) DFMO + 0.2mM Spermidine, 7) 0.2mM Spermine, 8) 5mM (or 35mM) DFMO 
+ 0.2mM Spermine.  The water and DFMO only treatments are controls useful for identifying 
baseline viability and inviability, respectively. Each treatment vial contained a total volume of 
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6mL. Generation of treatment vials and collection of 50 larvae was repeated three straight days 
to produce three replicates for each experiment.  
Vials were cultured at 25C throughout the experiment.  Vials were checked every day 
and scored based on initial pupariation and daily eclosure of adult flies.  The number of adult 
eclosures was recorded daily for twenty-one days after animals were first introduced into the 
vials or until no animals eclosed for three consecutive days if less than 21 days.  
The mean viability of the three replicates for all eight treatments groups was calculated 
for each experiment. Three independent experiments are completed for each fly cross. A one-
way ANOVA was used to test whether there existed a statistically significant difference between 
the mean viability for each treatment group across all three experiments. If the one-way ANOVA 
resulted in statistical significance, a Tukey HSD test was used to compare each treatment group 
and decipher in which treatment groups mean viability differed significantly. 
Fly Stocks 
Stock BL464 was used to generate stable CRISPR-Cas9 mutant fly lines.  Stock BL 
54590 was the parental strain used for embryo injections of gRNA plasmids and ssODN DNA 
for CRISPR-Cas9 modifications.  The wild-type stocks were as follows: Oregon R (BL25211), 
Canton S (BL64349), Hikone AS (BL4267) and Berlin K (BL8522). The RNAi stocks used were: 
anne (BL30499) and CG6230 (BL13333). BL 16262 contains a PiggyBac insertion within the B 
exon and the stock containing a minos insertion within the Z exon was BL 23396. All fly stocks 




Evidence in nematodes demonstrates that mutations in Catp5 can block the uptake of 
the polyamine norspermidine (7). Norspermidine is toxic in nematodes and mutations in Catp5 
restore viability. Catp5 encodes a P-Type5B ATPase (7) and a blast search revealed two close 
Drosophila orthologs to Catp5, anne and CG6230. anne is the only Drosophila gene encoding a 
P-Type5B ATPase. CG6230 encodes a highly related P-Type5A ATPase and is the only 
Drosophila gene encoding a P-Type5A ATPase. Both genes were tested for their ability to 
transport polyamines. 
A Novel Assay to Determine if Genes are Required for Polyamine Transport 
 To determine if anne or CG6230 are polyamine transporters we developed an in vivo 
assay in which animals must transport polyamines to survive. In this assay Drosophila larvae 
were cultured in the presence of a semi-lethal concentration of α-difluoromethylornithine 
(DFMO) which acts as an irreversible inhibitor of ODC (1, 2, 3, 5; Figure 1). We hypothesized 
that animals grown in the presence of a semi-lethal concentration of DFMO would be “obligated” 
to transport polyamines, and thus could be rescued by the addition of exogenous polyamines to 
the culture medium. Initial experiments were performed with four genetically unrelated wild-type 
strains (Figure 4). In each case viability was greatly reduced by DFMO and rescued by the 
addition of exogeneous polyamines. 5mM DFMO was chosen as the concentration at which 
maximum reduction in viability was observed and higher concentrations of DFMO did not further 
reduce viability. The addition of 0.4mM putrescine or 0.2mM spermidine or spermine to the 
media are the minimum concentrations needed to restore full viability in the presence of DFMO, 
although variability in the sensitivity of each wild-type strain to DFMO was observed (see 
appendix A for raw data). 
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The viability of wild-type larvae (Oregon R, Canton S, Hikone AS, Berlin K) cultured under 
different conditions is shown. Concentrations of DFMO and polyamines were 5mM (DFMO), 
0.4mM (putrescine) and 0.2mM (spermidine and spermine) respectively. Data represent the 
mean and SE of 3 independent experiments, each conducted in triplicate (n=50).  *** indicates a 
significant p-value (p<0.001) using a one-way ANOVA and Tukey HSD test. All other pairwise 
treatment comparisons were non-significant. 
Figure 4: An in vivo assay for polyamine transport. 
 
Next, we used the polyamine transport assay to test whether the Drosophila orthologs to 
Catp5, anne and CG6230 are polyamine transporters. We hypothesized that animals with a 
non-functional polyamine transport system will be inviable when grown in the presence of 
DFMO and exogenous polyamines, whereas viability would be restored if the polyamine system 
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was functional (Figure 5). We therefore assessed whether RNAi knockdown of anne or CG6230 
resulted in viability under obligate transport conditions.  We first tested anne using RNAi 
targeting the core 4 exon (see Figure 3A).   
 
 
Figure 5: Design of the assay to test polyamine transport by forcing animals to import 
polyamines in the presence of a semi-lethal dose of DFMO. 
 
Larvae expressing RNAi against the core 4 exon of anne, present in all isoforms, were 
collected and grown under obligate transport conditions. We observed 7.5% viability in animals 
exposed to DFMO, a drastic decrease compared to the water-only control (Figure 6A). When 
obligated to transport exogenous polyamines we observed a significant p-value (***p<0.001) 
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between treatment groups (PA vs PA+DFMO) indicating that knockdown of anne results in the 
inability of these animals to transport polyamines to circumvent DFMO toxicity. In contrast, 
animals expressing RNAi against CG6230 have viability rescued to levels comparable to the 
water-only control under obligate transport conditions, thus circumventing DFMO toxicity by 
importing exogenous polyamines (Figure 6B).  These results indicate that anne encodes a 





B.   
  
A.  Percent viability of progeny from anne RNAi (BL 30499) under obligate transport conditions.  
RNAi targets the core exon 4 (C4) of anne.  Data represents the mean and SE of 3 independent 
experiments (n=50), each conducted in triplicate.  A significant p-value (***p<0.001) was found 
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when treatment groups (PA vs PA+DFMO) were compared using a one-way ANOVA and Tukey 
HSD test. What about DFMO vs PA + DFMO? 
B. Percent viability of progeny from CG6230 RNAi (BL 44005) under obligate transport 
conditions.  Data represents the mean and SE of 3 independent experiments (n=50), each 
conducted in triplicate.  A non-significant p-value (p>0.05) was found when treatment groups 
(PA vs PA+DFMO) were compared using a one-way ANOVA and Tukey HSD test. What about 
water vs DFMO? 
Figure 6: Animals expressing RNAi against anne are inviable under obligate transport 
conditions. 
Polyamine Transport is Dependent Upon Alternatively Spliced 3’ and 5’ Isoforms  
Next, we investigated the role of the alternatively spliced 5’ A’A and B and 3’ YZ exons in 
polyamine transport (Figure 3B).  Our goal was to test whether multiple protein isoforms 
encoded by anne are required for polyamine transport. I 
A strain with a Piggybac (PBac) transposon insertion within the 5’ UTR of the B exon 
was tested under obligate transport conditions.  The 10kb PBac insertion occurs 193 bp 
upstream of the translation start codon (Figure 7A).  Animals with the PBac insertion were not 
rescued when treated with both polyamines and DFMO (Figure 7B) indicating that the B exon is 
required for polyamine transport.  To demonstrate that the insertion in the B exon was the cause 
of loss of polyamine transport activity, we excised the PBac transposon from exon B using a 
genetic strategy (see methods) that did not alter the wild-type sequence of the B exon.  Excision 
progeny from this cross were tested under obligate transport conditions. Excision of the PBac 
transposon rescued the viability of these animals indicating that polyamine transport had been 
restored (Figure 7C). Thus, the B exon is required for polyamine transport activity. 
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A.     
 





A.  Gene layout of anne containing a PiggyBac (PBac) transposon insertion into the 5’UTR of 
the B exon.  Translation start codons are signified by * and stop codons by **.   
B.  Percent viability of animals with PBac (BL16262) insertion grown under obligate transport 
conditions.  Data represents the mean and SE of 3 independent experiments (n=50), each 
conducted in triplicate.  A significant p-value (*p<0.001) was found when treatment groups (PA 
vs PA+DFMO) were compared using a one-way ANOVA and Tukey HSD test. 
C.  Percent viability of animals after PBac excision.  Data represents the mean and SE of 3 
independent experiments (n=50), each conducted in triplicate.  A non-significant p-value 
(p>0.05) was found when treatment groups (PA vs PA+DFMO) were compared using a one-way 
ANOVA and Tukey HSD test. 
Figure 7: Transposon insertion into the B exon inhibits polyamine transport ability under 
obligate transport conditions. 
 
We also studied the effect of a 2kb minos transposon insertion in the Z exon (Figure 8A).  
Disruption of the Z exon reading frame by minos reduced viability under obligate transport 
conditions, however the effects were less pronounced than with the B exon (compare Figures 
8B and 9B).  Z exon mutant animals were 30-40% viable compared to less than 5% for the exon 
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B mutation.  The transposon insertion in exon Z is approximately 120 bp upstream of the stop 
codon and likely results in a truncated protein missing a small fraction of the C-terminal region 
and leaving a majority of the protein intact. This result suggests isoforms containing the 
alternatively spliced YZ exon combination are necessary for polyamine transport and even small 







A.  Gene layout of anne containing a minos insertion upstream of the stop codon in the Z exon.  
Start codons are signified by * and stop codons by **.   
B.  Percent viability of animals (BL 23396) with a transposon insertion within the Z exon.  Data 
represents the mean and SD of 3 independent experiments (n=50), each conducted in triplicate.  
A significant p-value (*p<0.001) was found when treatment groups (PA vs PA+DFMO) were 
compared using a one-way ANOVA and Tukey HSD test. 
Figure 8: Transposon insertion into the 3’ alternatively spliced Z exon causes a 
reduction in viability under obligate transport conditions. 
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Generation of A’A Exon Deletion Mutants Using CRISPR-Cas9 Gene-Editing 
We have evidence that the B, YZ, and core exons are involved in polyamine 
transport.  However, no strains containing A’A exon-specific mutations, or RNAi against the A’A 
exons were available for study.  Therefore, I decided to use a CRISPR-Cas9 gene-editing 
strategy to mutate the A’A exon.  
CRISPR-Cas9 gene-editing is based on a bacterial immune system for targeting viral 
invasion (51).  These viral-specific nucleotide sequences, along with the repeated flanking 
sequences, are defined as ‘crRNA’ and transcribed by the bacterium.  The repeating sequence 
present on the crRNA is recognized by ‘tracrRNAs,’ which act as a “middle-man,” binding both 
the Cas9 endonuclease and crRNA, and guiding the Cas9 to a homologous double-stranded 
viral-specific nucleotide sequence.  Cas9 cleaves this region, causing a double-stranded break 
(51). 
This system has been co-opted for gene editing purposes by purifying the Cas9 
endonuclease and engineering a single chimeric “guide RNA (gRNA)” encompassing both the 
crRNA and tracrRNAs from the bacterial system.  The guide RNA (gRNA) contains a 20-
nucleotide long sequence which recognizes homologous genomic sequences upstream of a 
“protospacer adjacent motif (PAM)” sequence, guiding the Cas9 endonuclease to this specific 
location, forming the CRISPR-Cas9 complex (Figure 9A).  Cleavage occurs 3 base pairs 
upstream of the PAM sequence, inducing a double-stranded break (DSB), which is repaired by 
endogenous DNA repair mechanisms. 
The DSB break is repaired through one of two mechanisms; 1) non-homologous end 
joining (NHEJ) or 2) homology directed repair (HDR).  In the NHEJ pathway, addition or deletion 
of nucleotides around the DSB causes indels of variable size leading to disruption of gene 
function (Figure 9B).  In the HDR pathway, a donor template (either inserted donor sequence or 
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homologous chromosome) is used as a template for repairing the double-stranded break.  This 









A. Cas9 and gRNA target genomic DNA.  The Cas9 endonuclease recognizes a 5’-NGG-3’ 
PAM sequence on target DNA.  A 20nt long guide RNA (gRNA) recognizes homologous 
genomic sequences 20nt upstream of 5’-NGG-3’ region and guides Cas9 to this region forming 
the CRISPR-Cas9 complex.  The complex cleaves the target sequence leaving a double-
stranded break (DSB). 
B. DNA Repair pathways exploited by the CRISPR-Cas9 system.  gRNAs guide the Cas9 
endonuclease to a site in the genome where it induces a DSB and induction of DNA repair 
mechanisms.  The DSB break is repaired through one of two mechanisms:  1) non-homologous 
end joining (NHEJ) or 2) homology directed repair (HDR).  In the NHEJ pathway, addition or 
deletion of nucleotides around the DSB leads to variable indel lengths.  In the HDR pathway, a 
donor template (either inserted plasmid or homologous chromosome) is used as a template for 
repairing the double stranded break.  This leads to a precise insertion of donor template at the 
DSB. 
Figure 9: CRISPR-Cas9 gene editing system workflow (44, 50, 51). 
 
The CRISPR-Cas9 gene editing system has been widely adopted to induce transgenesis 
in D.melanogaster (41-50) and many variations in the CRISPR-Cas9 workflow exist based on 
the experimental goals of the project.  If a “defined deletion” of an entire genomic region is the 
objective, two gRNAs are designed flanking the targeted region, causing loss of genomic region 
through duplicate double-stranded breaks (44, 47, 50). 
 We used the CRISPR-Cas9 gene editing system to create a defined deletion 
encompassing the entire A’A exon (see Figure 13A). gRNAs were designed using the 
“FlyCRISPR” (44, 50, 51) algorithm to identify guide RNA (gRNA) sequences, and their potential 
off-target locations. Two gRNAs were used to cause a “defined deletion” of the entire A’A exon, 
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one flanking upstream of the A’A exon (A5p) and another flanking downstream of the exon 
(A3p).  
Next, we chose a strain expressing the Cas9 nuclease. A wide array of fly stocks which 
express Cas9 endogenously, under control of different regulatory elements, are available. A 
recent study quantified transgenesis efficiency for available fly stocks.  They found the Act5C-
Cas9, vasa-Cas9 (3), and nos-Cas9 (2) stocks to be the most efficient at undergoing 
transgenesis (44, 45) (see appendix B).  We limited our CAS9 strains to Act5C-Cas9 and vasa-
Cas9 which have high activity and ubiquitous expression.  
The efficiency of transgenesis reduces drastically if the Cas9 expressing fly stock 
contains single nucleotide polymorphisms within the sequence targeted by the gRNAs (43). To 
avoid this, both strains were sequenced around the gRNA target sites. No single nucleotide 
polymorphisms were observed in the gRNA target sites for the Act5C-Cas9 stock, while the 
vasa-Cas9 fly stock contained one SNP within the gRNA targeted region. Thus, we used the 
Act5C-Cas9 fly stock to avoid inefficient transgenesis (see appendix B).  
Animals that received embryo injections containing the gRNA plasmids (‘founders’, P0) 
were individually crossed to a 4th chromosome balancer fly stock to isolate the mutant allele. F1 
progeny were collected for each P0 individual and crossed to their siblings.  Once F2 larvae 
were present in F1 crosses, the F1 adults were removed and genotyped to identify founders 
which had the expected mutant allele (Figure 10). Successful mutagenesis should result in a 
band of around 500 base pairs relative to the wild-type sequence which should be 1700 base 
pairs (appendix B).  Most of the P0 individuals produced F1 with the 1700 base pair wild-type 
allele.  Only one of the P0 individuals genotyped, line 33A, produced F1 with a 500 base pair 
mutant allele. (Figure 10).  Thus, a successful gene-editing event occurred in the 33A P0 
individual. A homozygous stable line of 33A was prepared. Animals homozygous for founder 
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chromosomes were analyzed by genotyping and sequencing to confirm the germline 
transmission and isolation of the expected A’A mutant allele.  
 
   
PCR analysis to identify A’A deletion mutants. The lane labeled C is the wild-type allele from the injected 
strain Act5c-Cas9.  Each lane represents all the progeny of a F1 cross derived from a single P0 
founder.  Multiple crosses were set-up for each founder, which was denoted alphabetically with letter 
following the number representing the P0 founder. Note; Samples were overloaded to identify low 
frequency chromosomes in the population. 
Figure 10: PCR analysis of F1 individuals demonstrates successful germline 
transmission of the expected mutant A’A allele from founder generation. 
 
Positively identified A’A exon deletions were analyzed by Sanger sequencing.  
Alignment of the sequence to the wild-type sequence (Act5C-Cas9, the injected P0 fly line) 
shows that the entire region containing the A’A exon is missing, along with the gRNA target 
sequences, and that cleavage occurred at the predicted PAM site (Figure 11).  Therefore, the 








The isolated A’A exon mutant sequence is missing both the A’ and A exons.  The 500 base pair 
PCR product (Figure 10) was analyzed by Sanger sequencing and aligned using CLUSTAL 
MUSCLE multiple sequence alignment to the wild-type sequence (labeled “AseqPCR”).  The A 
exon is colored in yellow and the A’ exon is colored in gray.  Both of the gRNA target sites (A3p, 
A5p) are in neon green.  The PAM sites are underlined.   
Figure 11: Sequence analysis of the A’A CRISPR deletion mutation.  
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Before testing the ability of A’A mutant animals to transport polyamines under obligate 
conditions, we needed to identify whether any off-target cleavage had been induced by the 
gRNA-Cas9 complex.  “FlyCRISPR” Target Finder reported only one of the gRNAs used, A5p 
(targeting upstream of the A’A exon), had a potential off-target sequence. The potential off-
target site was analyzed by Sanger sequencing and aligned to the expected ‘wild-type’ 
sequence present on both parental chromosomes (Figure 12). No differences compared to the 




Sequences from two A’A deletion mutants are presented in comparison to the wild-type 
(Act5c-Cas9) line.   
Figure 12: No changes have occurred at the potential (A5p) off-target site A’A mutant 
lines. 
The A’A exon is not involved in polyamine transport 
The A’A deletion animals were tested for polyamine transport ability under obligate 
transport conditions.  Deletion of the A’A exons caused a slight but non-significant reduction in 
percent viability (80-90%) (Figure 13B).  Therefore, the 5’ A’A exon combination is not required 







A. CRISPR-Cas9 mutagenesis was used to create defined deletions of entire A’A exon.  gRNAs 
are pictured below the Figure flanking A’A.  The neon green portion of each gRNA signifies the 
genomic region homologous to the target sequence.  Black arrows represent forward and 
reverse PCR primers which amplify the area around gRNA target sites. 
B.  Percent viability of A’A exon deletion animals.  Data represents the mean and SE of 3 
independent experiments, each conducted in triplicate (n=50).  A non-significant p-value 
(p>0.001) was found when treatment groups (PA vs PA+DFMO) were compared using a one-
way ANOVA and Tukey HSD test. What about water and DFMO? 
Figure 13: Animals carrying an A’A exon deletion have normal viability when rescued 




Polyamines are vital at the cellular level for all domains of life. Despite the identification 
of several components of the transport system a clear picture of the transport mechanism 
remains elusive. There is good evidence that polyamines are sequestered in endosomal 
vesicles and controlled release of polyamines from endosomes may be important in regulating 
intracellular polyamine levels (10, 11, 20). Polyamine transport components have been 
identified in diverse cell types, raising the possibility that our current understanding of the 
transport mechanism is being clouded by the existence of tissue-specific transporter 
components. In addition, most studies have been carried out in cell culture rather than in vivo. 
The identification of the P-type ATPase encoded by anne as a polyamine transporter is an early 
step in expanding studies of polyamine transport to a specific tissue in a living organism. As 
Drosophila larvae ingest polyamines, they must be absorbed by gut transporters. The inability of 
anne insertional mutants and RNAi knockdown animals to transport polyamines strongly 
suggests that anne encodes a component of a gut transporter. Our conclusion that a P5B-type 
ATPase is required for polyamine transport is supported by recent finding that two human 
orthologs of anne, ATP13A2 and ATP13A3 are also able to transport polyamines (55, 56, 57). 
The Drosophila P5B-type ATPase Encoded by anne is a Polyamine Transporter 
The Drosophila gene anne is a complex locus encoding a P5B-type ATPase with six 
different protein isoforms, all of which contain a transport domain composed of five core exons 
(Figure 3C).  Animals expressing RNAi targeting the core exons were inviable when obligated to 
transport exogenous polyamines suggesting that at least one of the six protein isoforms is 
involved in polyamine transport. 
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We investigated whether 5’ and 3’ alternatively spliced exons are involved in polyamine 
transport.  Animals with a PiggyBac transposon inserted into the 5’UTR of the 5’ B exon were 
inviable under obligate transport conditions but were rescued to wild-type viability levels when 
the PiggyBac transposon was excised.  A minos transposon insertion near the C-terminal end of 
the 3’ Z exon caused animals to have reduced viability when compared to wild-type under 
obligate transport conditions.  Together, these observations suggest that the B, Z, and core 
exons are required for polyamine transport. We used CRISPR-Cas9 gene editing to generate 
animals with a deletion of both the A’ and A exons.  These animals were rescued under obligate 
transport conditions indicating the A’/A exon pair does not transport polyamines.  
A similar CRISPR approach was used in an attempt to delete the entire X exon. A 
mutant line containing a scar from CRISPR-Cas9 mutagenesis was observed in multiple 
lineages.  However, Sanger sequencing of the scar indicates an intact X exon with 
approximately 750bp missing in the intronic region between the core 5 and X exons (appendix 
B). This result suggests that loss of the X exon causes lethality, so long as the remainder gene 
is present.  Further study will be needed to test this hypothesis. 
We also attempted to use CRISPR to create a mutant with an inactive phosphorylation 
domain (Figure 3C) by substituting alanine for the highly conserved aspartic acid residue 
responsible for activity. We were also unable to isolate this mutant. However, approximately half 
the P0 crosses analyzed contained a nucleotide change within the PAM site, which prevents 
recurring cleavage of the targeted DNA after Cas9 induces a double-stranded break. Thus, a 
mutational event did occur raising the possibility that loss of the catalytic aspartic acid is lethal. 
How these observations might tie into our inability to isolate an X exon deletion is currently 
unknown but worthy of further investigation. 
Our data suggest that multiple functions are encoded within the gene with different 
protein isoforms having different functions. A recent study showing anne plays a critical role in 
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ovary morphology and reproductive success supports this conclusion (53). This observation 
also might offer an explanation for why, despite genomic scars due to mutagenesis, it was not 
possible to isolate animals with the X exon deleted or substitute the aspartic acid for alanine at 
the phosphorylation site. The activity of the conserved aspartic acid residue and the X exon 
might be essential for either autoregulation or reproductive success. 
Human Orthologs to anne are Involved in Polyamine Transport 
The Drosophila genome has a single P-type 5B ATPase. We have shown that one of the 
protein isoforms of anne is not required for polyamine transport and that this single gene is 
multifunctional based on the protein isoforms.  
There are four P-type 5B ATPases in humans designated ATP13A2-5. These likely 
evolved through the process of gene duplication and sub-functionalization resulting in tissue 
specificity and variation in function. In contrast the Drosophila gene is ancestral with multiple 
functions encoded in a single gene. Both ATP13A2 and ATP13A3 are ubiquitous while 
ATP13A4 and ATP13A5 are restricted by tissue type (55). Both ATP13A2 and ATP13A3 are 
present in endocytosis but vary in their expression. ATP13A3 is expressed in early/recycling 
endosomes while ATP13A2 is expressed within late endosomes and lysosomes (34). 
Identification of these genes as components of the mammalian polyamine transport system 
helps explain how polyamine uptake occurs through endocytosis, binding herapan sulfate on 
glypican-1 on the plasma membrane (55).  
Clinical significance of identifying anne as a polyamine transporter 
Understanding how the P-type 5B ATPase sub-family interact with polyamines could 
open up new areas of cancer research by identifying a target for therapy. Tumor cells require 
high polyamine concentrations to sustain rapid growth and proliferation (1,2,3,5).  A clinically 
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approved drug, α-difluoromethylornithine (DFMO), is highly effective at inhibiting biosynthesis by 
acting as an irreversible inhibitor of ODC. (Figure 1) However many tumors circumvent the 
effects of DFMO by up-regulating polyamine uptake (3,5) Thus, a combined therapy that targets 
biosynthesis and transport may be more effective in treating cancers. 
Additionally, our polyamine transport assay might be useful as a model for malignancy. 
Conceptually, one could imagine that polyamine transport could exist in two states that can be 
either basal or obligate and that distinct transport systems might be involved. Basal transport 
might be reflective of normal cells in the body that for the most part are able to manage 
polyamine homeostasis through a combination of biosynthesis, influx and efflux. Malignant cells 
on the other hand have a high requirement for polyamines and activated transport systems. Our 
assay, which requires transport under obligate conditions may be more reflective of conditions 
in malignant cells. Thus, our assay could be useful in identifying genes up regulated in tumors to 
maintain the high concentration of polyamines required for their growth. 
The human orthologs, ATP13A1-5, appear to play a role in neurological disorders. 
ATP13A2 has been demonstrated to provide protection against Parkinson’s disease 
(32,33,34,35,36,37,38) and a recent study illustrated that a loss of a functional ATP13A2 results 
in lysosome rupture, cathepsin B activation, and ultimately neurological disorders such as 
Parkinson’s disease (57). The ability of ATP13A2 to transport polyamines, specifically spermine, 
protects cells against mitochondrial dysfunction and reactive oxygen species by increasing 
polyamine uptake in both the cell and mitochondria (56).  
Additionally, mutations around the ATP binding domain within ATP13A3 were shown to 
be involved in heritable pulmonary arterial hypertension (63). Pulmonary arterial hypertension is 
caused by proliferation of pulmonary vascular smooth muscles cells (VSMCs) leading to 
increased constriction. This process occurs in a polyamine dependent manner whereby, 
polyamines are required for sustaining VSMC proliferation (64). Further work is required to 
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understand the connection between ATP13A3, pulmonary arterial hypertension, and polyamine 
homeostasis. 
Future Work 
A more detailed characterization of a complete transporter is urgently needed and anne 
could play a role in achieving this objective. For example, a tandem affinity purification mass 
spectrometry approach (62) using anne as bait could be used to identify the components of a 
Drosophila gut transporter complex. The isolation of such a complex and identification of its 
components could answer many outstanding questions such as whether multiple transport 
systems with tissue specific components exist and whether some components are ubiquitous. 
The existence of ubiquitous components would be important for cancer therapy alleviating the 
need to identify the specific components of a tumor complex.  Such experiments could also lead 




APPENDIX A: WHOLE ANIMAL ASSAY DATA 
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Part 1: Wild-type Whole Animal Assay Data 
We developed an in vivo assay to create obligate transport conditions and falsify our null 
hypothesis.  First, standard viability was measured by growing animals on standard fly 
food.  Next, a toxic dose of DFMO was identified by treating the food with increasing 
concentrations of DFMO.  A sufficiently toxic dosage of DFMO completely inhibits polyamine 
biosynthesis and thus cause in viability compared to the water only control.  Viability was 
rescued by obligating animals to bypass DFMO inhibited biosynthesis through transport of 
exogenously supplemented polyamines (putrescine, spermidine, and spermine).  To create 
obligate transport conditions, we set-up vials supplemented with an increasing dosage of 
polyamines and DFMO until viability was rescued (Table 1,2,3).  Toxic doses of DFMO (5-
35mM; fly lineage-dependent) and rescuing dose of polyamines (PUT = 0.4mM, SPD =0.2 mM, 
SPM = 0.2mM) were identified through titration experiments (Data not shown).  
Table 1: Raw data for Wild-type animals (Oregon R) grown under obligate transport 




Table 2: Raw data for Wild-type animals (Canton S) grown under obligate transport 




Table 3: Raw data for Wild-type animals (Hikone AS) grown under obligate transport 





Table 4: Raw data for Wild-type animals (Berlin K) grown under obligate transport 
conditions are rescued in presence of DFMO. 
 
Part 2: Obligate Transport Assay to Test Polyamine Transport Ability of Core, B, and Z 
Exons. 
With our experimental methodology validated, we assessed whether knockdown of anne 
or CG6230 with RNAi showed reduced viability under obligate transport conditions.  We 
identified RNAi lines, with induced RNAi expression targeting Core 4 exon of anne.  Each RNAi 
line was crossed to an Actin-GAL4 line to drive RNAi expression.  Animals expressing RNAi 
against anne under obligate transport conditions were 7.5% viable, which is a drastic decrease 
compared to the water only control.  (Table 4).  In contrast, animals expressing RNAi against 
CG6230 have viability rescued 100% to similar levels as the water only control when 
experiencing obligate transport conditions (Table 5).  These results suggest anne encodes a 
polyamine transporter and CG6230 does not.  
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Table 5: Raw data for RNAi targeting core exon 4 (C4) of anne grown under obligate 




Table 6: Raw data for RNAi targeting CG6230 grown under obligate transport conditions 




Animals expressing RNAi against the core 4 exon are not rescued under obligate 
transport conditions.  However, anne encodes multiple alternatively spliced protein isoforms, all 
of which contain the core exons.  We reasoned the function in polyamine transport of the 5’ and 
3’ alternatively spliced exons could be deduced by perturbing function of each exon individually 
and measuring viability under obligate transport conditions (Table 6, 7, 8). 
Table 7: Raw data for fly stock containing 10kb PBac insertion in B exon grown under 




Table 8: Raw data for fly stock excised of PBac insertion from B exon grown under 




Table 9: Raw data for fly stock containing 2kb minos insertion in Z exon grown under 




Table 10: Raw data for fly stock without A'A exon pair grown under obligate transport 




APPENDIX B: CRISPR-CAS9 MODIFICATION OF A, X, AND 
CONSERVED ASPARTIC ACID RESIDUE 
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Part 1: Guide RNAs (gRNAs) and Single-stranded Donor Design 
The first step to knockout the entire X exon and substitute an inactive alanine for the 
highly conserved aspartic acid residue was to design guide RNAs (gRNAs) targeting the X exon 
and the core 5 exon.  We used the FlyCRISPR algorithm to identify gRNA target sites limiting 
potential off-target locations. An output is generated with a list of potential gRNA sequences 
homologous to the target sequence, as well as potential off-target sites (41, 43, 47).  All 
designed gRNA sequences and potential off-targets are listed in Figure 18A. 
Two gRNAs flanking the X exon were constructed to create defined deletions (Figure 
16A).  Only one gRNA was necessary to target the end of core 5 exon and generate mutants 
with a single amino acid substitution (Figure 16B).  A single-stranded donor was constructed to 
serve as a template for CRISPR-Cas9 induced Homology-directed repair (HDR) and generate 
animals with an alanine substituted for the conserved aspartic acid responsible for 
phosphorylation and ATPase activity.  The designed ssODN was 200 nucleotides long with 75-
100 nucleotides sharing homology upstream (5’) and downstream (3’) of the targeted sequence 
(Figure 16B).   
Two-point mutations were introduced within this donor template; 1) a point mutation 
(missense) substituting an alanine for the aspartic acid residue hypothesized to be responsible 
for catalytic activity (GAC->GCC) and 2) a point mutation at the PAM site (TGG->TCG) that 
conserves the wild-type amino acid sequence of the PAM site (Figure 10B).  The second 
modification is necessary to prevent continuous cleavage by Cas9.  The Cas9 cleavage site is 
upstream of the intended substitution, and thus to account for the directionality of the repair 
process, the reverse complement of the ssODN was used (Figure 16B). 
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A.   
 
B.   
 
A.  Design of guide RNAs to create defined deletions of the A and X exons.  gRNAs are pictured 
below Figure flanking A’A and X exons.  Neon green portion of gRNA signifies region 
homologous to target sequence.  Black arrows represent forward and reverse PCR primers 
which amplify area around gRNA target sites. 
B.  Design of guide RNA and ssODN to substitute an alanine for the highly conserved aspartic 
acid residue at the end of the core 5 exon.  gRNA is pictured above Figure.  Neon green portion 
of gRNA signifies region homologous to target sequence.  Black arrows represent forward and 
reverse primer sequences to PCR flanking regions around gRNA target sites.  The intended 
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nucleotide changes are shown in red (PAM site) and green (aspartic acid-to-alanine).  The wild-
type sequence is the top sequence.  The bottom sequence is the donor sequence, which is 
flanked by upstream (HA-L) and downstream (HA-R) homologous arms. 
Figure 14: Design of guide RNAs and single-stranded donor for CRISPR-Cas9 
mutagenesis. 
Part 2: Construction of pU6-BbsI-chiRNA Plasmid to Drive gRNA Expression 
All gRNA oligos were annealed, phosphorylated, and ligated into a linearized pU6-BbsI-
chiRNA plasmid (Figure 17A).  Plasmids were then analyzed by Sanger sequencing for the 
correct gRNA sequence between the BbsI cut site by alignment to pU6-BbsI-chiRNA plasmid 






CLUSTAL multiple sequence alignment by MUSCLE (3.8) 
pU6 (-)             GTTGATCATTTATATAGGTATGTTTTCCTCAATACTTCGNNNNNNNNNNNNNNNNNNNN 
X3p gRNA            GTTGATCATTTATATAGGTATGTTTTCCTCAATACTTCGTCGTACGGACGTCATGATCC 
A3p gRNA            GTTGATCATTTATATAGGTATGTTTTCCTCAATACTTCGAACGAAGACTGCTACTCAGA 
X5p gRNA            GTTGATCATTTATATAGGTATGTTTTCCTCAATACTTCGCTCCAGGCTCTCTGAGAGAG 
A5p gRNA            GTTGATCATTTATATAGGTATGTTTTCCTCAATACTTCGATTAAATTCTTAGTATGAC- 
C3p gRNA            GTTGATCATTTATATAGGTATGTTTTCCTCAATACTTCGATCTCCTAGGTCTATAAATG 
                    ***************************************                    
pU6 (-)             GTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGT 
X3p gRNA            GTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGT 
A3p gRNA            GTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGT 
X5p gRNA            GTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGT 
A5p gRNA            GTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGT 
C3p gRNA            GTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGT 
                    ************************************************************ 
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A.   Workflow to generate pU6-BbsI-chiRNA plasmid with specific gRNA sequences.  pU6-BbsI-
chiRNA is cleaved by BbsI restriction enzyme.  Oligos with gRNA sequence are phosphorylated, 
annealed, and then ligated into cut pU6-BbsI-chiRNA plasmid.  DmU6 promoter drives 
expression of gRNAs when injected into embryos. 
B.  Alignment of Sanger sequencing data to verifying gRNAs have been correctly incorporated 
into pU6 plasmid.  Yellow highlighted region is location of expected gRNA insertion in pU6 
plasmid.  All sequences were aligned to pU6 (-), which is the uncut sequence.  All sequences 
were aligned using CLUSTAL MUSCLE multiple sequence alignment algorithm. 
Figure 15: All generated pU6-BbsI-gRNA vectors contain the expected gRNA sequence 
necessary to drive CRISPR-Cas9 mutagenesis (50). 
Part 3: Identification of Candidate Fly Stocks for CRISPR-Cas9 Mutagenesis 
A plethora of stocks expressing Cas9 nuclease endogenously have been generated for 
CRISPR-Cas9 induced transgenesis.  After a pool of candidate’ fly lines had been identified, we 
needed to sequence around each gRNA target site to control for potential polymorphisms within 
the gRNA sequence.   A single nucleotide change, depending on the location in relation to the 
gRNA and PAM sequences, could result in substantial drop in gRNA efficiency or out-right 
failure of the CRISPR-Cas9 gene editing system (43, 50).  Sanger sequencing was done to 
compare the sequences across multiple candidate stocks (Figure 18A). We found unexpected 
polymorphisms in the vasa-Cas9 stock within the sequence targeted by the X5p gRNA. 
Conversely, the gRNA target sequences for all designed gRNAs were identical to the Act5c-
Cas9 stock (Figure 18C). Thus, Act5c-Cas9 was chosen for mutagenesis since no SNPs were 














Aseq RVR TCCGGGTGATGAGAGCAAAG 1700 500 
Xseq 
FWD CAATAGCCGAGTCGATCTAAC 1379 250 






RVR CAATAGCCGAGTCGATCTAAC 533 533 
 
B.   
Name (Chromosome) Stock Center Number Ubiquitous activity Germline-restricted activity 
act-Cas9 (X) BL54590 (+) (-) 
vasa-cas9 (X) BL51323 (+) (-) 
vasa-cas9 (3) BL51324 (+) (-) 
nos-cas9 (2) NIG CAS-0001 (-) (+) 
 
C. 
Act5c-Cas9 (X) & Vasa-cas9 (III) Core 5 gRNA target: 
vas             AAAGCGGCTAAAGACTAGTGAAATATTTTGCATATCTCCTAGGTCTATAAATGTGGCAGGA 
act5c           AAAGCGGCTAAAGACTAGTGAAATATTTTGCATATCTCCTAGGTCTATAAATGTGGCAGGA 
anne         AAAGCGGCTAAAGACTAGTGAAATATTTTGCATATCTCCTAGGTCTATAAATGTGGCAGGA 
                ************************************************************* 
vas             GCATAAATTGTTGTTGCTTTGACAAGGTTCGTACCATTAATATGTTCTGTATTGATTTAGG 
act5c           GCATAAATTGTTGTTGCTTTGACAAGGTTCGTACCATTAATATGTTCTGTATTGATTTAGG 
anne         GCATAAATTGTTGTTGCTTTGACAAGGTTCGTACCATTAATATGTTCTGTATTGATTTAGG 
                ************************************************************* 
Act5c-Cas9 (X) & Vasa-cas9 (III)  X5p gRNA target: 
vas             CGCCATACGATTTTCTTACACACGATTTTTTTTGGGCTGGTGGCTCTAGAGGTGGTTCTC 
act5c           CGCCATACGATTTTCTTACACACGATTTTTTTTGGGCTGGTGGCTCTAGAGGTGGCTCTC 
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anne         CGCCATACGATTTTCTTACACACGATTTTTTTTGGGCTGGTGGCTCTAGAGGTGGCTCTC 
                ******************************************************* **** 
vas             CAGGCTCTCTGAGAGAGCGGACAGCTCTATAGCCAGCACCTTTCTTTCTCGCATACAGTG 
act5c           CAGGCTCTCTGAGAGAGCGGACAGCTCTATAGCCAGCACCTTTCTTTCTCGCATACAGTG 
anne         CAGGCTCTCTGAGAGAGCGGACAGCTCTATAGCCAGCACCTTTCTTTCTCGCATACAGTG 
                ************************************************************ 
Act5c-Cas9 (X) X3p gRNA target: 
act5c      AAATAAAAAAATTTATATTAAGCCCTTCTGTTCGTACGGACGTCATGATCCTGGGAATTA 
anne         AAATAAAAAAATTTATATTAAGCCCTTCTGTTCGTACGGACGTCATGATCCTGGGAATTA 
                ************************************************************  
act5c           TAAAAGCTAGAAATGTACTGTTAGGCATGCATAAGTTTATTTGCATAAACAATATATCAT 
anne         TAAAAGCTAGAAATGTACTGTTAGGCATGCATAAGTTTATTTGCATAAACAATATATCAT 
                ************************************************************ 
Act5c-Cas9 (X) A5p gRNA target: 
act5c           TACTTTTTTGCACAGACTACTAAAGTTCATCATTCTTAATTACCATTGCCAAGAAATTCG 
anne         TACTTTTTTGCACAGACTACTAAAGTTCATCATTCTTAATTACCATTGCCAAGAAATTCG 
                ************************************************************ 
act5c           CACCTGTCATACTAAGAATTTAATCCGAGGGATTGTATCGTAATGAATTCATATCAAGGT 
anne         CACCTGTCATACTAAGAATTTAATCCGAGGGATTGTATCGTAATGAATTCATATCAAGGT 
                ************************************************************ 
Act5c-Cas9 (X) A3p gRNA target: 
act5c           TTTAGCTTGTTAATTACTGTTGACAATTTTTTTTTGTCTACTCGCGAGAATAACAAAAAA 
anne         TTTAGCTTGTTAATTACTGTTGACAATTTTTTTTTGTCTACTCGCGAGAATAACAAAAAA 
                ************************************************************ 
act5c           AGGATGCACCATCGATTTCCCTCTGAGTAGCAGTCTTCGTTGCTTTTGCTTTTGATTTTC 
anne         AGGATGCACCATCGATTTCCCTCTGAGTAGCAGTCTTCGTTGCTTTTGCTTTTGATTTTC 
                ************************************************************ 
A.  Table of PCR primers for genotyping and sequencing around region with gRNA target 
sites.  The expected size of PCR fragment listed in last two columns for the expected wild-type 
and mutant sequences. 
B.  Summary of Cas9 activity for different fly stocks expressing Cas9 endonuclease under 
different regulatory elements.  Table summarizing lines created, their effectiveness, and 
references to each line and their tested optimization.  Chromosome of insertion listed in 
parentheses after the name of each stock.  The activity of these lines, either ubiquitous or 
restricted to germline, are compared using (+) or (-).   
C.  Sequence alignment of two candidate stocks identified a single nucleotide polymorphism in 
vasa-Cas9 (3) fly stock.  The wild-type sequence was used as a comparison 
(anne).  Alignments were done using Sanger sequencing data and CLUSTAL MUSCLE multiple 
 62 
sequence alignment algorithm.  PAM site is underlined.  Highlighted region is homologous to 
gRNA target sequence. 
Figure 16: Act5c-Cas9 (X) fly stock is ideal candidate for undergoing CRISPR-Cas9 
mutagenesis. 
Part 4: Cross to Generate Stable Fly Lines and Molecular Screen to Identify A and X 
Exon Mutants 
F1 progeny from each P0 individual injected with the X exon gRNAs was screened for 
transmission of the X exon mutant allele using PCR and gel electrophoresis. The expected 
mutant allele should be approximately 250 base pairs for X mutants (Figure 18A).  Only a few 
potential mutant alleles were present within the F1 population.  Lines 18B, 22C, 22D, 27B, and 
28B have bands of potential (faint) bands around 250-750 base pairs.  For most of the F1 lines, 
however, only the wild-type band is present, and thus no germline transmission from founder 





Note; Gel was overloaded to identify low frequency chromosomes in population.   
Identification of germline transmission of mutant alleles within X exon F1 population.  PCR 
product from the injection stock, Act5c-Cas9 (X), is present as a negative control for 
transgenesis (C). Each lane denotes an F1 cross derived from a single P0 founder.  Multiple 
crosses were set-up for each founder, which was denoted alphabetically with letter following the 
number representing the P0 founder.    
Figure 17: Analysis of F1 demonstrates the germline transmission of multiple mutant 
alleles from founder generation for X exon mutant. 
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After identifying F1 populations containing the expected X mutant allele, F2 progeny 
were backcrossed with a balancer stock to isolate individual alleles from the F1 
populations.  Heterozygous F3 siblings were then crossed to generate stable fly lines containing 
only the balancer and a single isolated founder chromosome.  F3 that were homozygous for 
founder chromosomes were analyzed by genotyping to identify F2 crosses that were positive for 
the expected mutant chromosomes.   
A majority of X exon F2 crosses analyzed produced only wild-type genotypes when 
analyzed on a gel (not pictured).  However, when one F1 lineage (27B) was analyzed, 2 out of 4 
analyzed F2 crosses were identified as heterozygous for a mutant allele of approximately 750 
bases (Figure 19A).  The expected mutant allele should be 250~ base pairs long, which cannot 
be visualized on the gel, demonstrating that an unintended gene-editing event occurred.   
Regardless, it is possible the X exon was lost, or damaged and the remaining 500 base 
pair left behind composes the intronic region between the core 5 exon and the start of the Y 
exon.  The 750bp band was excised from gel and analyzed by Sanger sequencing.  Alignment 
of the sequencing read to the wild-type sequence (Act5c-Cas9) demonstrates the entire X exon 
is intact (Figure 20B).  The 500 missing bases are part of the intronic region between the core 5 
exon and X exon and must have been excised during CRISPR-Cas9 mutagenesis.  Thus, I was 







A.  Genotyping X exon F2 population by PCR and gel electrophoresis.  Each lane denotes F2 
crosses derived from a single F1 lineage (27B).  Multiple crosses were set-up for each 
founder.  These are denoted numerically with letter following the number representing the 
representative F1 cross. 
B.  The isolated X exon mutant allele contains the entire X exon coding sequence.  The 750 
base pair band from F2 line 27B.15 (pictured Figure 14A; lane 15) was excised from the gel, 
purified, analyzed by Sanger sequencing, and aligned using CLUSTAL MUSCLE multiple 
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sequence alignment to the wild-type sequence.  “XseqPCR” sequence is the wild-type 
sequence.  The X exon is colored in dark green (colored text signifies coding region vs. 
3’UTR).  The X3p gRNA target site is in neon green.  PAM site is underlined.  Deleted intronic 
region between core 5 exon and the X exon not pictured.   
Figure 18: Analysis of mutant X exon F2 lines reveals a loss of the intronic region and 
an intact X exon. 
Part 5: Cross to Generate Stable Fly Lines with Alanine Substituted for Aspartic Acid 
Residue 
Founder animals who underwent transgenesis (P0 generation), were individually 
crossed to a balancer stock.  F1 siblings were crossed and analyzed by Sanger sequencing for 
germline transmission of intended mutant allele.   
The F1 chromatograms were analyzed for multiple peaks at both the PAM and 
phosphorylation site (aspartic acid residue) as this implies there are multiple alleles present 
within the F1 population.  Most of the analyzed F1 lines were wild-type for both the PAM and 
phosphorylation sites (not pictured).  However, four lines (12A-D) from the founder line 12, had 
multiple peaks on the chromatogram at both sites, representing potential population of 
heterozygotes (Figure 21A). 
One line, 20A, gave a peculiar read which aligned with the wild-type sequence until three 
base pair upstream of the PAM site.  Afterwards, the read aligned with a region approximately 
300 base pair downstream from cut site (Figure 21B).  Since Cas9 cleaves three base pair 
upstream of the PAM site, the same location the read mis-aligns with the wild-type sequence, 
this strongly suggests that a rogue DNA repair event occurred, whereby an entire region 300bp 
downstream of the PAM site was removed.  This was replicated twice, to make sure this 
observation wasn’t an error due to PCR or sequencing, producing identical results.   
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Although this result was unintended, it is nonetheless interesting.  Further investigation 
of the sequence revealed that removal of the end of core 5 causes a frameshift and premature 
stop codon approximately 30bp downstream of the cut site, where the wild-type and mutant 
sequence diverge (Figure 13C).  A premature stop codon means this mutant allele lacks the 
aspartic acid residue as well as the 3’ exons (C-terminus protein isoforms X/YZ), representing a 








A.  Multiple potential mutant F1 lineages were identified using Sanger sequencing 
data.  Multiple peaks are expected for mutant lineages at both the PAM site (TGG->TcG; left) 
and aspartic acid-to-alanine site (GAC->GcC; right).  Each lane denotes an F1 cross derived 
from a single P0 founder.  Multiple crosses were set-up for each founder, which was denoted 
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alphabetically with letter following the number representing the P0 founder.  The chromatogram 
of the injection stock, Act5C-Cas9 (X), is shown as the ‘wild-type (WT)’ sequence.   
B.  A potential “null” mutant was identified by comparison of Sanger sequencing chromatogram 
to wild-type (Act5C) sequence.  Sanger sequencing chromatograms were used to identify 
mutant alleles within the F1 population.  The PAM site (TGG) is underlined and denoted with an 
arrow.  Cut site occurs approximately 3bp upstream from PAM site, which is denoted with a 
triangle.  The wild-type sequence (WT; Act5c) aligns with the 20A F1 stock until the cut site, 
where the sequences diverge. 
Figure 19: Analysis of Asp2Ala F1 demonstrates the germline transmission of multiple 
mutant alleles from founder generation. 
 
Individual F2 progeny from both F1 lines 20A and 12A were backcrossed to a balancer 
stock to isolate potential mutant alleles.  Twelve F2 crosses were created in an attempt to 
isolate the ‘null’ allele from the F1 line 20A. Only three of these crosses produced 
progeny.  Nineteen total F2 crosses of the 12A founder lineage produced progeny.   
F3 progeny were analyzed by Sanger sequencing to identify positive F2 crosses and 
selfed to create stable fly lines for each potential mutant allele.  Based on the chromatogram 
and alignments, none of the 20A F2 crosses contain the null allele, as they were wild-type for 
both the PAM and phosphorylation site (Figure 21A).  Eight of the nineteen 12A F2 crosses 
were wild-type for both the PAM and aspartic acid residue.  Eight of the nineteen 12A F2 
crosses were mutant at the PAM site, but not as the aspartic acid residue (Figure 21B).   
The remaining three of 12A F2 crosses (23A, 43A, 43F) aligned with each other, but not 
the wild-type sequence.  When the sequence is used in a nucleotide BLAST search, all three 
sequences align to a region on the third chromosome (3L) 96%.   
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Thus, it is possible these sequences represent another unintended gene-editing event, 
where an off-target region on the 3L chromosome, sharing very loose homology to anne, was 













A.  Analysis by Sanger sequencing demonstrates no recovery of the null allele from the 
20A F1 line.  Pictured are the chromatograms analyzing both PAM site and aspartic acid 
residue for 20A F2 crosses are pictured.  Wild-type (WT) chromatogram is the sequence from 
Act5C-Cas9 (X) line.  The last three base pairs on the left-hand chromatogram are the PAM site 
(TGG).  The aspartic acid residue is encoded by GAC of chromatogram on right-hand 
side.  Only one 20A F2 cross is pictured (20A.6).   
B.  Analysis of the 12A F2 crosses by Sanger sequencing demonstrates recovery of a 
mutant allele with a mutation at the PAM site, but not the phosphorylation site.  Pictured 
are the chromatograms analyzing both PAM site and aspartic acid residue for 12A F2 crosses 
are pictured.  Wild-type (WT) chromatogram, from Act5C-Cas9 (X) line, is pictured below.  The 
expected nucleotide changes for both the PAM site (TGG) and aspartic acid residue (GAC) are 
denoted by “*” on top of sequence alignment.  Each represented 12A F2 line is represented on 
the left-hand side of graphic.  
Figure 20: Analysis of mutant Aspartic-to-alanine F2 reveals unexpected mutagenesis. 
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It appears a few gene-editing events took place in the attempt to substitute an alanine 
for the aspartic acid residue.  A potential null mutant was created in 20A but never 
recovered.  Approximately half of the F2 crosses recovered from the 12A founder lineage 
contained a mutant PAM site (TGG->TcG) ‘scar’ from transgenesis.  Unfortunately, none of 
these lines appear to have the expected substitution at the phosphorylation site (GAC->GcG) 
Three of the F2 crosses from the 12A founder lineage had sequences which align with 
each other, but not anne.  They share 96% identity with a region on L arm of the third 
chromosome.  The gRNA used to target the end of the core 5 exon of anne had one potential 
off-target site on the 3rd chromosome.  Therefore, I hypothesize this off-target site was used as 
a template for homology-directed repair creating a chimeric gene.  It is possible this is a null 
mutant since the end of the core 5 exon and thus aspartic acid residue do not appear to be 
present.  Further, if another chromosome was used as a template for DNA repair, both of the 
alternatively spliced 3’ exons (X, YZ) could be missing as well.  It might be worth investigating 
whether these mutant lines lack a polyamine transport phenotype under obligate transport 
conditions.  If this is observed, it would be worth better characterizing the mutant allele in these 
crosses to understand the actual effect on the anne locus.  However, verification and work will 
need to be done to confirm this event occurred as perceived.  Reliability of data from such a 
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